Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPEASED II
NCT05702463Phase 1Recruiting
- Sponsor
- Montréal Heart Institute
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aspirin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Montréal Heart Institute. Primary endpoints: Screening rate at 1 year, Enrollment rate by proportion of referred eligible participants at 1 year and 3 more. Started Jun 2023; status: recruiting.
02
Drugs
aspirin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05702463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05702463.